ECE2022 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (318 abstracts)
The role of deferoxamine (DFO) in insulin resistance and diabetes
So-Yeon Ahn 1 , Min Woo Song 2 , Jae Yeop Jeong 2 , Tae Ho Kim 3 , Sung-E Choi 4 , Yup Kang 4 , Hae Jin Kim 2 , Ja Young Jeon 2 , Seung JIN Han 2 , Nami Lee 2 & Kwan-Woo Lee 2
1Busan Bumin Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine, Busan, Rep. of South Korea; 2Ajou University School of Medicine, Department of Endocrinology and Metabolism, Suwon, Rep. of South Korea; 3Seoul Medical Center, Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul, Rep. of South Korea; 4Ajou University School of Medicine, Department of Physiology, Suwon, Rep. of South Korea
Iron also plays an important role in many physiological processes, including redox balance, inflammation, and metabolism. It is reported perturbation of iron (Fe) homeostasis has also been associated with metabolic diseases. Iron reduction, with iron chelator, has preventive effects in cardiovascular remodeling and obesity. On the other hand, deferoxamine (DFO) increases hypoxia and collagen production in the kidney. Thus, the effects of DFO on metabolic disease remains controversial. As a result, we investigated the effects of DFO on obesity, inflammation, insulin resistance, and diabetes in db/db mice models with type 2 diabetes. An in vivo study was performed on 7-week-old db/db mice. Mice were treated with DFO (100 mg/kg) or placebo every other day for 16 weeks. After treatment, an intraperitoneal glucose tolerance test and immunohistological examinations were performed. Fasting insulin and serum lipid levels were measured at the end of the study. Also, genes involved in inflammation and lipid metabolism were analyzed by real-time PCR. The DFO treated mice showed improved obesity, insulin resistance, and decreased levels of plasma inflammatory cytokines, total cholesterol, free fatty acid, and triglycerides. Fasting glucose in mice was also reduced by DFO treatment. Immunoblot analysis shows transferrin receptor 1 (TfR1) levels were increased in skeletal muscles of db/db mice models with type 2 diabetes. But DFO treatment decreased transferrin receptor 1 (TfR1) levels in skeletal muscles. DFO treatment also attenuated inflammatory cytokines and lipid deposition in the liver. Therefore, we consider the fine tuning of iron levels through DFO treatment as highly suggestive for preventing and/or treating insulin resistance and diabetes.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more